Hamza Hashmi

30PUBLICATIONS
112CO-AUTHORS
Medical bacteriologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical mycologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Jul 20, 2026
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

|Apr 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Doris K Hansen, Danai Dima, Hira Mian

|Apr 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve

|Mar 21, 2026
Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Cindy Varga, Myra Robinson, James A Davis

|Aug 25, 2025
Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance.

Ross S Firestone, Anish K Simhal, Devin McAvoy

|Mar 11, 2025
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma.

Rachel Dileo, Prerna Mewawalla, Kalaivani Babu

Pageof 5

Frequent Collaborators

9 joint publications

Saad Z Usmani

9 joint publications

Heather Landau

8 joint publications

Sridevi Rajeeve

8 joint publications

James A Davis